Müller N, Empl M, Riedel M, Schwarz M, Ackenheil M
Psychiatric Hospital, Ludwig Maximilian University, Munich, Germany.
Eur Arch Psychiatry Clin Neurosci. 1997;247(6):308-13. doi: 10.1007/BF02922260.
The cytokines interleukin-2 (IL-2) and interleukin-6 (IL-6) increase during immune activation, they are released from activated astrocytes and microglial cells in the central nervous system (CNS), and they are able to enhance the catecholaminergic neurotransmission. This study focused on the soluble receptors of IL-2 and IL-6 (sIL-2R, sIL-6R) as a part of the regulation system of IL-2 and IL-6. We studied serum levels of sIL-2R in 30 schizophrenic patients not under neuroleptic medication during an acute exacerbation of the disease and reexamined these patients under neuroleptic treatment after clinical improvement. The sIL-6R levels of 39 schizophrenic patients were estimated under the same conditions. The results were compared with the levels of sIL-2R and sIL-6R in 42 healthy controls. No difference was found between the schizophrenic patients before neuroleptic treatment and the healthy controls. During neuroleptic treatment, however, there was a significant increase of sIL-2R levels and a significant decrease of the sIL-6R levels between the pre- and post-conditions. In comparison with healthy controls, the treatment group also showed increased sIL-2R levels and decreased sIL-6R levels. These results suggest that treatment with neuroleptics is associated with increased sIL-2R and decreased sIL-6R. Since sIL-2R bind and inactivate IL-2, whereas sIL-6R form an active complex with IL-6, the increase of sIL-2R and the decrease of sIL-6R together may reflect a functional down regulation of these activating cytokines. This suggests that neuroleptic therapy has a differentiated immunomodulatory effect.
细胞因子白细胞介素-2（IL-2）和白细胞介素-6（IL-6）在免疫激活过程中会增加，它们从中枢神经系统（CNS）中活化的星形胶质细胞和小胶质细胞释放出来，并且能够增强儿茶酚胺能神经传递。本研究聚焦于IL-2和IL-6的可溶性受体（sIL-2R、sIL-6R），将其作为IL-2和IL-6调节系统的一部分。我们研究了30例未服用抗精神病药物的精神分裂症患者在疾病急性加重期的血清sIL-2R水平，并在临床症状改善后对这些患者进行抗精神病药物治疗时再次进行检测。在相同条件下对39例精神分裂症患者的sIL-6R水平进行了评估。将结果与42名健康对照者的sIL-2R和sIL-6R水平进行比较。未服用抗精神病药物的精神分裂症患者与健康对照者之间未发现差异。然而，在抗精神病药物治疗期间，治疗前后sIL-2R水平显著升高，sIL-6R水平显著降低。与健康对照者相比，治疗组的sIL-2R水平也升高，sIL-6R水平降低。这些结果表明，抗精神病药物治疗与sIL-2R升高和sIL-6R降低有关。由于sIL-2R结合并使IL-2失活，而sIL-6R与IL-6形成活性复合物，sIL-2R升高和sIL-6R降低可能共同反映了这些激活细胞因子的功能性下调。这表明抗精神病药物治疗具有差异化的免疫调节作用。
